Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Alzheimerâ€™s disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27552
This Agreement initially contemplates a transfer of existing Alzheimer Therapeutic Know-how to Licensee. Pursuant to such initial transfer and continuing collaboration thereafter, it is contemplated that Licensee will determine the amino add sequence of proteins and base sequence of nucleic acids, generate monoclonal antibodies, done and express and assess biological and therapeutic activity of proteins, all related to the Field of this Agreement.
In addition, Licensee will engage in a collaborative research project directed to the Field and funded by Licensee, which collaboration is contemplated to include
a. development by Licensee of therapeutics based on specific materials provided; and
b. other related research and development related to the development by Licensee of therapeutics for Alzheimer's disease.
IPSCIO Record ID: 262864
IPSCIO Record ID: 291175
University Research Technology shall mean all University Patents and all University Know-How.
University Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor
which claim Pre-Existing Inventions and which are identified hereto; or
which claim inventions that are made, in whole or in part, by students or employees of SAMSF during the term and in the course of the Research Project;
with the exception of all such patents which are Corporation Patents as hereinafter defined.
U.S. Patent Application Serial No. 08/801,301, filed February 18, 1997 entitled Use if Nekatibub To Prevent Cytotoxic effects of Amyloid Protein by Pappolla.
U.S. Provisional Patent Application Serial No. 60/075,555 filed February 23, 1998 entitled Use of 3-Indol-Proprionic acid by Pappolla
U.S. Provisional Patent Application Serial No. 60/079,349 filed March 25, 1998 entitled Inhibition of Alzheimer of Alzheimer Beta-Fibrillogenesis by Mela Tonm by Pappolla.
Corporation Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor which claim inventions that are made, in whole or in part, by students or employees of Corporation.
Research Technology shall mean all University Patents, University Know-How, Corporation Patents and Corporation Know-How.
IPSCIO Record ID: 5850
DEVELOPMENT PROGRAMS. means pharmaceutical, biotechnological and diagnostic development programs in the field of Alzheimer's Disease and other central nervous system and neurodegenerative diseases as performed by LICENSEE or its Affiliates.
LICENSED TECHNOLOGY. means (a) mice of the Tg 2576 strain of the transgenic mouse model described in Hsiao et al, Correlative Memory Deficils, A-Beta Elevation and Amyloid Plaques in Transgenic Mice, as published in Science on October 4, 1996, or in a U.S. continuation-in-part patent application, filed June 17, 1996, Serial No. 08/664,872 (the â€œCIP Applicationâ€), which mice are (1) progeny of a cross of a Tg2576 N2 male with a C57B6SJL female or (2) the progeny of a cross between (Tg2576 N2 x C57B6SJL) male with a C57B6SJL female, (such mice referred to herein asâ€ Stockâ€); (b) progeny of the Stock; and (c) certain transgenic mice that may result from the Sponsored Research Activities.
IPSCIO Record ID: 203273
Licensor hereby grants each Licensee a non-exclusive license, with the right to grant sublicenses, under the Licensed Patents to research, develop, use, have used, make, have made, offer for sale, sell, have sold, import and export Licensed Products other than Bapineuzumab Products in the Field in the Territory.
The patents relate to DNA Encoding Recombinant Antibody Molecules End Specific for Amyloid ÃŸ Peptide.
AÃŸ Peptide shall mean P-amyloid protein which is the cleavage product of amyloid precursor protein, occurring predominantly as a (1-39) to (1-43) amino acid.